Is Cann Group Threatened by Cann Global?, page-128

Its 37.5% of the 1yr demand of 8,000kg so that is factually correct. Y2 of CAN total market metrics implies 30,000kg so QBL would be infinitesimally smaller (10%) assuming steady production level based on that deal. Also using CAN metrics to back-solve, it implies Medcan needs 2,000m2 of production capacity to meet the supply quantity of the Bonify deal. Do they have it and if not have QBL costed and disclosed it?CAN's phase 3 capacity targets 40,000 to 50,000kg which can place it to be a large player domestically and globally.

The other issue is that QBL investors seem to focus on QBL biggest potential against the smallest metrics for the Aussie market and CAN's phase 1 plans (apples and oranges comp to make QBL better than it seems). CAN are funded to build a global business, with production phased capacity in, and are supported by both key private players (Aurora, who made an opportunistic bid given strategic benefit of geo diversity and scale of supply) and the Vic government, who are supporting CAN via contracts, regulatory support etc.. to make Vic a central location for medicinal cannabis (i.e. build off local Vic talent in broader pharma capability).

Unless I have missed it by not reading 131 pages of patched together prospectus, I note that QBL haven't quantified the value of the Bonify deal, even using an average market rate for bud or some parameters of value. The quantity may be impressive but without an idea on price, it could potentially be much less value than hoped. Any ideas on that?